Lodo Therapeutics Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lodo Therapeutics Corp.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
Genentech is to work with microbiome therapeutics company Microbiotica in a collaboration to discover, develop and commercialise treatments for inflammatory bowel disease.
Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
- Digital Health
Drug Discovery Tools
- Natural Products
- Drug Discovery Tools
- Other Names / Subsidiaries
- Conifer Point Pharmaceuticals, LLC
- Hibiskus Biopharma, Inc.